Kymera Therapeutics (KYMR) total debt

Total debt · fiscal 2025
$82.25M

Kymera Therapeutics (KYMR) carried total debt of $82.25M at the end of fiscal 2025 (December 31, 2025). That is 6.3% lower than the $87.76M of fiscal 2024. Figures as of 18 Nov 2026, 08:15 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Total debt, fiscal 2025
$82.25M
Change on fiscal 2024
−6.3%
Highest on record
$87.76Mfiscal 2024
Lowest on record
$17.34Mfiscal 2022
Fiscal years on record
42022–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Kymera Therapeutics total debt, in more detail

Across the 4 fiscal years on record (2022–2025), the highest was $87.76M in fiscal 2024 and the lowest $17.34M in fiscal 2022.

Total debt was 0.1× shareholders' equity at the end of fiscal 2025.

History · 4 fiscal years

Total debt by fiscal year

Kymera Therapeutics total debt, year by year

Kymera Therapeutics (KYMR) total debt by fiscal year
Fiscal yearTotal debtChangeYear endedDebt ÷ equity
2025$82.25M 6.3% down0.1×
2024$87.76M 3.6% up0.1×
2023$84.67M 388.5% up0.2×
2022$17.34M—0.0×

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.

How to read it

Debt magnifies results in both directions — set it against cash, equity and the profit available to pay the interest rather than reading it alone.

Total debt at health care companies of similar size

Total debt of Kymera Therapeutics and comparable companies
CompanyTotal debtFiscal year
Fresenius Medical Care FMS€10.80B2025
Kymera Therapeutics KYMR$82.25M2025
DaVita DVA$12.87B2025
Halozyme Therapeutics HALO$2.14B2025
Universal Health Services UHS$5.17B2025
Repligen RGEN$689.95M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on KYMR

Kymera Therapeutics, figure by figure

Kymera Therapeutics (KYMR) overview: price, valuation and scorecardAll health care companies by market value

Kymera Therapeutics total debt: questions and answers

How much debt does Kymera Therapeutics have?

Kymera Therapeutics (KYMR) carried total debt of $82.25M at the end of fiscal 2025 (December 31, 2025). That is 6.3% lower than the $87.76M of fiscal 2024.

What are the highest and lowest total debt figures on record for Kymera Therapeutics?

Across the 4 fiscal years on record (2022–2025), the highest was $87.76M in fiscal 2024 and the lowest $17.34M in fiscal 2022.

How does Kymera Therapeutics's debt compare with its equity?

Total debt was 0.1× shareholders' equity at the end of fiscal 2025.

How is Kymera Therapeutics's total debt calculated?

Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Kymera Therapeutics (KYMR) total debt”, data as of 18 November 2026. https://funkfolio.com/stock/KYMR/total-debt

Underlying data: the company's filings with the SEC and Yahoo Finance.